Evotec SE (FRA:EVT)

Market Cap	1.28B
Revenue (ttm)	796.97M
Net Income (ttm)	-196.08M
Shares Out	n/a
EPS (ttm)	-1.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,642,601
Average Volume	1,025,536
Open	7.03
Previous Close	6.83
Day's Range	6.96 - 7.35
52-Week Range	5.06 - 14.22
Beta	n/a
RSI	65.95
Earnings Date	May 6, 2025

About Evotec SE

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio-metabolic disorders; and animal and women health. It ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 4,740
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EVT

Financial Performance

In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.